2. Search Result
Search Result
Results for "

trabecular

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112879
    Mito-TEMPO
    Maximum Cited Publications
    164 Publications Verification

    		 Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    Mito-TEMPO
  • HY-16926
    CK-666
    20+ Cited Publications

    		 Arp2/3 Complex HIV Infection Cancer
    CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC50=12 μM). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation .
    CK-666
  • HY-B0191
    Bimatoprost

    AGN 192024

    		 Prostaglandin Receptor MMP Cardiovascular Disease Endocrinology
    Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus .
    Bimatoprost
  • HY-129630
    Tetrahydrocortisol

    		Microtubule/Tubulin Neurological Disease Cancer
    Tetrahydrocortisol is a cortisol metabolite that inhibits dexamethasone-induced formation of cross-linked actin networks. Tetrahydrocortisol can be used in the research of primary open-angle glaucoma, glucocorticoid-induced ocular hypertension, Lewis lung carcinoma, and EMT-6 mouse breast cancer .
    Tetrahydrocortisol
  • HY-12798
    Netarsudil
    1 Publications Verification

    AR-13324

    		 Monoamine Transporter ROCK Cardiovascular Disease Neurological Disease
    Netarsudil (AR-13324) is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
    Netarsudil
  • HY-12798B
    Netarsudil hydrochloride
    1 Publications Verification

    AR-13324 hydrochloride

    		 ROCK Cardiovascular Disease Neurological Disease
    Netarsudil (AR-13324) hydrochloride is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil hydrochloride reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil hydrochloride is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
    Netarsudil hydrochloride
  • HY-125944
    MitoTEMPO hydrate
    Maximum Cited Publications
    164 Publications Verification

    		 Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    MitoTEMPO hydrate
  • HY-P1759
    N-CBZ-Phe-Arg-AMC

    Z-FR-AMC

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC
  • HY-19518
    Latanoprostene bunod

    NCX116; LBN

    		 Prostaglandin Receptor Neurological Disease
    Latanoprostene bunod (NCX116; LBN) is a nitric oxide-releasing prostaglandin F2α analog. Latanoprostene bunod is a prodrug that, upon instillation into the eye, is hydrolyzed by corneal esterases into two active metabolites: Latanoprost (HY-B0577) and NO. Latanoprost activates the prostaglandin FP receptor to increase the outflow of aqueous humor through the uveoscleral pathway. NO increases aqueous humor drainage through the trabecular meshwork pathway, achieving synergistic enhancement targeting the dual pathways of aqueous humor outflow. Latanoprostene bunod can be used in research related to open-angle glaucoma and ocular hypertension .
    Latanoprostene bunod
  • HY-12798A
    Netarsudil dimesylate
    1 Publications Verification

    AR-13324 dimesylate

    		 ROCK Cardiovascular Disease Neurological Disease
    Netarsudil (AR-13324) dimesylate is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil dimesylate reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil dimesylate is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
    Netarsudil dimesylate
  • HY-16758
    Verosudil

    AR-12286

    		 ROCK Neurological Disease
    Verosudil (AR-12286) is a ROCK inhibitor. Verosudil has equal inhibitory activity against ROCK1 and ROCK2 (Ki: 2 nM). Verosudil is less selective for PKA, PKCT, MRCKA, and CAM2A (Ki: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil increases trabecular outflow capacity to reduce intraocular pressure. Verosudil is useful in the study of glaucoma and ocular hypertension .
    Verosudil
  • HY-W008951
    Ethylenediaminetetra(methylenephosphonic acid)

    EDTMP

    		 Radionuclide-Drug Conjugates (RDCs) Neurological Disease Cancer
    Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
    Ethylenediaminetetra(methylenephosphonic acid)
  • HY-P5522A
    TriDAP dihydrochloride
    1 Publications Verification

    L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride

    		 NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV Infection Inflammation/Immunology
    TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
    TriDAP dihydrochloride
  • HY-128538
    Sepetaprost

    ONO-9054

    		 Prostaglandin Receptor Neurological Disease
    Sepetaprost (ONO-9054) is a dual agonist of the prostaglandin E3 receptor and prostaglandin F receptor. Sepetaprost reduces intraocular pressure in animal models. Sepetaprost is applicable for research on ocular hypertension and open-angle glaucoma .
    Sepetaprost
  • HY-P5522
    TriDAP

    L-Ala-γ-D-Glu-meso-diaminopimelic acid

    		 NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV Infection Inflammation/Immunology
    TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
    TriDAP
  • HY-19518R
    Latanoprostene bunod (Standard)

    NCX116 (Standard); LBN (Standard)

    		 Reference Standards Prostaglandin Receptor Neurological Disease
    Latanoprostene bunod (NCX116; LBN) (Standard) is the analytical standard of Latanoprostene bunod. This product is intended for research and analytical applications. Latanoprostene bunod is a nitric oxide-releasing prostaglandin F2α analog. Latanoprostene bunod is a prodrug that, upon instillation into the eye, is hydrolyzed by corneal esterases into two active metabolites: Latanoprost (HY-B0577) and NO. Latanoprost activates the prostaglandin FP receptor to increase the outflow of aqueous humor through the uveoscleral pathway. NO increases aqueous humor drainage through the trabecular meshwork pathway, achieving synergistic enhancement targeting the dual pathways of aqueous humor outflow. Latanoprostene bunod can be used in research related to open-angle glaucoma and ocular hypertension.
    Latanoprostene bunod (Standard)
  • HY-158821
    ISTH0036

    		TGF-beta/Smad Neurological Disease
    ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
    ISTH0036
  • HY-151189
    ROCK-IN-4

    		ROCK Others
    ROCK-IN-4 is a potent ROCK inhibitor maintaining NO releasing ability. ROCK-IN-4 reversibly depolymerizes F-actin, and suppresses mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be used for glaucoma or ocular hypertension research .
    ROCK-IN-4
  • HY-148698
    2MD

    		VD/VDR Others
    2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
    2MD
  • HY-172634
    8-Iso-17-phenyl trinor prostaglandin F2β

    8-Iso-17-phenyl PGF2β

    		 Biochemical Assay Reagents Drug Isomer Others
    8-Iso-17-phenyl trinor prostaglandin F2β is an isomer of Bimatoprost (HY-B0191). Bimatoprost is a prostaglandin analog. Bimatoprost lowers intraocular pressure by regulating scleral and trabecular outflow.
    8-Iso-17-phenyl trinor prostaglandin F2β
  • HY-B0191R
    Bimatoprost (Standard)

    AGN 192024 (Standard)

    		 Reference Standards Prostaglandin Receptor MMP Cardiovascular Disease Endocrinology
    Bimatoprost (Standard) is the analytical standard of Bimatoprost. This product is intended for research and analytical applications. Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus [4] .
    Bimatoprost (Standard)
  • HY-176133
    ROCK-IN-12

    		ROCK Inflammation/Immunology
    ROCK-IN-12 (compound R3) is a selective ROCK inhibitor. ROCK-IN-12 can be used in the study of glaucoma .
    ROCK-IN-12
  • HY-16758A
    Verosudil hydrochloride

    AR-12286 hydrochloride

    		 ROCK Neurological Disease
    Verosudil (AR-12286) hydrochloride is the hydrochloride form of Verosudil (HY-16758). Verosudil hydrochloride is a ROCK inhibitor. Verosudil hydrochloride has equal inhibitory activity against ROCK1 and ROCK2 (Ki: 2 nM). Verosudil hydrochloride is less selective for PKA, PKCT, MRCKA, and CAM2A (Ki: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil hydrochloride increases trabecular outflow capacity to reduce intraocular pressure. Verosudil hydrochloride is useful in the study of glaucoma and ocular hypertension .
    Verosudil hydrochloride
  • HY-125641A
    AL-34662 formate

    		5-HT Receptor Neurological Disease
    AL-34662 (formate) is a 5-HT2 receptor agonist (IC50: 0.8-1.5 nM). AL-34662 (formate) stimulates inositol phosphate turnover and Ca 2+ release in human ciliary muscle cells (h-CM) (E50: 289 nM) and human trabecular meshwork cells (h-TM) (E50: 254 nM). AL-34662 (formate) can be used in studies to lower intraocular pressure (IOP) .
    AL-34662 formate
  • HY-183905
    KR-67607

    		11β-HSD Glucocorticoid Receptor Reactive Oxygen Species (ROS) Keap1-Nrf2 Neurological Disease
    KR-67607 is a selective 11β-HSD1 inhibitor, with an IC50 value of 4.8 nM against h11β-HSD1 and 7.1 nM against mouse 11β-HSD1. KR-67607 inhibits stress-induced Glucocorticoid receptor nuclear translocation, reduces cortisol levels, suppresses the expression of ROS and proinflammatory cytokines, and enhances Nrf-2-mediated antioxidant gene transcription. KR-67607 maintains trabecular meshwork structure and reverses elevated intraocular pressure. KR-67607 improves ocular antioxidant activity and mucus secretion, reverses ocular surface damage, and prevents ischemia-reperfusion induced ocular injury. KR-67607 can be used in research related to glaucoma and dry eye disease .
    KR-67607
  • HY-175085
    17-Phenyl trinor 8-iso prostaglandin E2

    		Drug Derivative Endocrinology
    17-Phenyl trinor 8-iso prostaglandin E2 is a prostaglandin analog that reduces intraocular pressure (IOP) in both normal and glaucomatous monkey eyes. 17-Phenyl trinor 8-iso prostaglandin E2 lowers IOP primarily by increasing trabecular outflow facility .
    17-Phenyl trinor 8-iso prostaglandin E2
  • HY-180195
    Grp94-IN-3

    		HSP Integrin Neurological Disease Cancer
    Grp94-IN-3 (Compound 47) is a selective ATP competitive inhibitor of Grp94, with a Kd value of 76 nM. Grp94-IN-3 has a much lower affinity for Hsp90α, with a Kd value of 9.17 μM. Grp94-IN-3 induces the degradation of integrin α2 (Integrin α2) in MDA-MB-231 cells and reduces the intracellular accumulation of mutant cardiac proteins in human trabecular meshwork cells. Grp94-IN-3 can be used for the study of metastatic cancer and open-angle glaucoma .
    Grp94-IN-3
  • HY-180916
    CAII-IN-11

    		Carbonic Anhydrase Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Neurological Disease
    CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma .
    CAII-IN-11
  • HY-182516
    Aminobutane bisphosphonate

    		Farnesyl Transferase Infection Others
    Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi. Aminobutane bisphosphonate inhibits proliferation of intracellular amastigote Trypanosoma cruzi and lacks activity against non-infective epimastigote forms. Aminobutane bisphosphonate reduces osteoclastic bone resorption, osteoid surface extent, and osteoclast number per mm of bone surface. Aminobutane bisphosphonate can be used for the research of american trypanosomiasis (chagas' disease) and immobilization-related bone loss .
    Aminobutane bisphosphonate
  • HY-183283
    CAII-IN-15

    		Carbonic Anhydrase Apoptosis NOD-like Receptor (NLR) Interleukin Related Reactive Oxygen Species (ROS) Neurological Disease
    CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma .
    CAII-IN-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: